European Consensus Statement on congenital hypogonadotropic hypogonadism — pathogenesis, diagnosis and treatment
Summary
Expert consensus on CHH, a disorder caused by deficient GnRH production, secretion, or action. Identified 25+ causal genes and established that pulsatile GnRH therapy can restore fertility. Noted that 10-20% of patients exhibit spontaneous recovery of reproductive function.
Key Findings
- Over 25 genes identified as causal for congenital hypogonadotropic hypogonadism
- Pulsatile GnRH therapy can induce fertility in most CHH patients
- 10-20% of patients show spontaneous recovery of reproductive function
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction
Wu HM, Chang HM, Leung PCK
Frontiers in Neuroendocrinology
Comprehensive review of GnRH signaling in reproductive biology. Documented extra-hypothalamic GnRH receptors in ovary, endometrium, and myometrium. Discussed new developments including oral nonpeptide GnRH antagonists and upstream regulators like kisspeptin for controlling the HPO axis.
- Extra-pituitary GnRH receptors exist in ovary, endometrium, and myometrium with direct effects
- New oral nonpeptide GnRH antagonists are being developed for clinical application
Clinical uses of gonadotropin-releasing hormone analogues
Casper RF
Canadian Medical Association Journal
Foundational clinical review of GnRH analog applications including endometriosis, uterine leiomyoma, precocious puberty, and hormone-dependent cancers. Established that GnRH agonists first stimulate then inhibit gonadotropin secretion through pituitary receptor downregulation, with few side effects.
- GnRH agonists downregulate pituitary receptors, producing reversible chemical gonadectomy
- Proved efficacious for endometriosis, fibroids, precocious puberty, and hormone-dependent cancers